Press Releases

View Archive: 2008 | 2007

11.12.08
Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting with FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders

7.22.08
Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients with Urea Cycle Disorders

4.28.08
Hyperion Therapeutics Names Bruce F. Scharschmidt CMO

4.7.08
Hyperion Therapeutics Elects Lota Zoth to Board of Directors

2.25.08
Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients with Hepatic Encephalopathy

2.7.08
Hyperion Therapeutics to Present at BIO CEO Investor Conference

1.21.08
Hyperion Therapeutics, Inc. Names Mark Spring Senior Vice President and Chief Financial Officer

1.7.08
William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman

Recent Press Releases